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Objective: Tissue-based xenografts such as cartilage are rejected within weeks by humoral and cellular
mechanisms that preclude its clinical application in regenerative medicine. The problem could be
overcome by identifying key molecules triggering rejection and the development of genetic-engineering
strategies to counteract them. Accordingly, high expression of a1,2-fucosyltransferase (HT) in xenogeneic
cartilage reduces the galactose a1,3-galactose (Gal) antigen and delays rejection. Yet, the role of com-
plement activation in this setting is unknown.
Design: To determine its contribution, we assessed the effect of inhibiting C5 complement component in
a1,3-galactosyltransferase-knockout (Gal KO) mice transplanted with porcine cartilage and studied the
effect of human complement on porcine articular chondrocytes (PAC).
Results: Treatment with an anti-mouse C5 blocking antibody for 5 weeks enhanced graft survival by
reducing cellular rejection. Moreover, PAC were highly resistant to complement-mediated lysis and
primarily responded to human complement by releasing IL-6 and IL-8. This occurred even in the absence
of anti-Gal antibody and was mediated by both C5a and C5b-9. Indeed, C5a directly triggered IL-6 and IL-
8 secretion and up-regulated expression of swine leukocyte antigen I (SLA-I) and adhesion molecules on
chondrocytes, all processes that enhance cellular rejection. Finally, the use of anti-human C5/C5a anti-
bodies and/or recombinant expression of human complement regulatory molecule CD59 (hCD59)
conferred protection in correspondence with their speciﬁc functions.
Conclusions: Our study demonstrates that complement activation contributes to rejection of xenogeneic
cartilage and provides valuable information for selecting approaches for complement inhibition.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Porcine cells/tissues could be obtained under controlled condi-
tions and used for xenogeneic applications to treat patients in
need1e3. Currently, porcine acellular matrices are used in clinical
practice for reconstructive surgery4, and together with pig cells, are
used as basic raw materials in tissue-engineering research3,5.: C. Costa, IDIBELL, Hospital
spitalet de Llobregat, 08908
7426.
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ology and Gastroenterology,
Epidemiology, Bristol-Myers
s Research Society International. PNevertheless, the rejection process of cell/tissue-based xenografts
needs better understanding to allow the development of strategies
that ensure engraftment and clinical use. In this respect, relevant
advances have been made in the ﬁeld of cartilage repair by iden-
tifying key molecules and pathways responsible for rejection of
porcine chondrocytes3,6,7. Porcine cartilage transplanted into pri-
mates is rejected by a slow process mediated by humoral and
cellular responses in which the galactose a1,3-galactose (Gal) an-
tigen plays a key role8,9. These observations were reproduced in
a1,3-galactosyltransferase-knockout (Gal KO) mice grafted with pig
engineered cartilage, in which a1,2-fucosyltransferase (HT)
expression markedly reduced Gal antigen expression, averted the
elicited anti-Gal antibody response and diminished the cellular
immune inﬁltrate within the grafts3. Despite these advances, the
contribution of complement to the rejection process of xenogeneic
cartilage remained unclear.
Complement activation by the classical pathway is the main
mechanism leading to hyperacute rejection of pig vascularized or-
gans transplanted into primates and contributes to acute humoralublished by Elsevier Ltd. All rights reserved.
R. Sommaggio et al. / Osteoarthritis and Cartilage 21 (2013) 1958e1967 1959xenograft rejection (AHXR)10e12. Accordingly, there is increasing
consensus about the need to continue using transgenic approaches
directed towards complement inhibition in addition to the Gal KO
pigs for development of solid organ xenotransplantation11,12.
Interestingly, recent work pointed out a role of complement acti-
vation in rejection of pig corneal xenografts13. Consistent with
initial observations in mice, an increase in C3a was detected in the
aqueous humor of rhesus monkeys with rejecting pig corneas.
These ﬁndings support the concept that complement activation
contributes to rejection of avascular xenografts, but the mecha-
nisms are unclear.
Different complement components play different roles in the
course of an inﬂammatory response14e17. The classical pathway
generates sequentially membrane-bound C4b, C3b and the com-
plex C5b-9 as well as the production of anaphylatoxins C4a, C3a and
C5a. C4 and C3 breakdown products are ligands for complement
receptors expressed on immune cells and promote immune func-
tions such as B cell activation and phagocytosis14,15. The membrane
attack complex (C5b-9, MAC), generated by the classical, alternative
and lectin pathways, leads to cytolysis, and together with the
anaphylatoxins (C5a being the most potent) promotes inﬂamma-
tion15e17. Importantly, the complement system is involved in
physiological and pathological processes of cartilage16,17. Chon-
drocytes themselves are capable of producing most complement
components of the classical pathway with most found in synovial
membranes and ﬂuid16,17. Complement activation most surely
contributes to cartilage injury as both the alternative and the
classical pathways are activated by released matrix fragments16,18.
In addition, further activation can be produced when trauma (or
surgical intervention) involves bleeding, providing another source
of complement and other potentiating proteins19.
Lastly, a role of complement is described for arthritis16e18,20e25.
In osteoarthritis (OA), complement activity participates in the
active inﬂammatory phase and is enhanced by pro-inﬂammatory
cytokines which stimulate local synthesis of complement pro-
teins16,21. Their differential expression and function in OA takes
them into consideration as biomarkers22,25. Complement activation
is also observed in rheumatoid arthritis (RA), which prompted the
assessment of complement inhibitors in small animal models of the
disease16,20,23. The high efﬁcacy of the anti-C5 blocking antibodies
in this setting led to the ﬁrst clinical trials24 and is the focus of
further developments23.
Here, we have assessed the contribution of complement to
rejection using pig chondrocytes exposed to human serum and
engineered pig cartilage grafted into Gal KO mice. This study de-
termines the potential efﬁcacy of targeting C5 for complement in-
hibition in this setting.
Materials and methods
Antibody production, puriﬁcation and analysis
BB5.1 hybridoma producing the anti-mouse C5 monoclonal
antibody (mAb) was obtained from Hoffmann-La Roche Ltd. (Basel,
Switzerland), and antibody thereof used under kind permission of
Hycult Biotech (Uden, Netherlands) who currently owns BB5.1
rights. The isotype-control-mAb hybridoma was HFN7.1 (ATCC).
Both were initially cultured in DMEM/20% FBS, gradually adapted to
serum-free Hybridoma SFM medium (Life Technologies) and
transferred into CELLine CL 1000 bioreactors (IBS Integra Bio-
sciences AG, Chur, Switzerland) for antibody production.
Antibody was puriﬁed using HiTrap MabSelect SuRe 1-ml col-
umns and buffer exchanged in PBS using HiTrap Desalting columns
following manufacturer’s instructions (GE Healthcare). Purity was
veriﬁed by 8%-SDS-PAGE under non-reducing conditions andCoomassie-blue staining. All samples were below 1 EU/ml
endotoxin.
The BB5.1 dose needed for C5 inhibition was determined by
pharmacodynamic studies in Gal KO mice that we maintain highly
inbred in a hybrid genetic background (B6xCBAx129sv)26. For the
experiment shown, Gal KO male mice were injected i.p. with PBS,
20mg/kg BB5.1 or control mAb at time 0 and 7 days later. Bloodwas
collected at various indicated times prior to injection and serum
obtained for complement activity determinations.
A hemolytic assay was developed to assess BB5.1 activity. Rabbit
RBC were prepared from 400 ml of rabbit blood, washed twice and
resuspended in 3.6 ml HBSS (Sigma). For the pharmacodynamic
study,10 ml of each serumwere dilutedwith 40 ml HBSS in V-bottom
96-well plate and incubated with 15 ml RBC in duplicates at 37C for
30 min. For the in vitro studies, BB5.1 was added to the mixture at
the indicated concentrations. After complement activation, the
plates were centrifuged (3000 rpm for 5 min) and supernatants
(40 ml) were transferred to 96-well plates for absorbance deter-
mination at 415 nm in a BioTek PowerWaveXS microplate reader
(BioTek Instruments, Winooski, VT, USA).
Porcine articular chondrocytes (PAC) isolation, culture and
engineering
PAC were isolated from control and HTAT20 transgenic pigs,
cultured and tissue-engineered as described3,6. All PAC were
assayed between passages 3 and 6. PAC expressing human com-
plement regulatory molecule CD59 (hCD59) were generated by
retroviral transduction. We obtained pCR2.1/hCD152-hCD59
(Alexion Pharmaceuticals) and subcloned it into EcoRI and XhoI
sites of the retroviral vector pLXSN using Takara reagents. Con-
structs were transfected into PG13 packing cells (ECACC) using
Lipofectamine-2000 (Life Technologies), viral supernatants were
collected after 48 h, ﬁltered and stored (80C). PAC were infected
for 10 h with viral supernatants in the presence of 0.8 mg/mL hex-
adimethrine bromide (Sigma) and 48 h later, cultured in selection
with 500 mg/mL G418 up to 2 weeks.
Transplant studies
Following procedures accepted by local ethical committee, 6e8-
months-old male Gal KO mice were equally distributed between
experimental groups to receive either control or HT-transgenic
cartilage with or without complement inhibition. Ten-mg pieces
of engineered cartilage were implanted subcutaneously as
described3. Seven mice received control or HT grafts without
further treatment. The other transplant cohorts were subjected to
systemic complement inhibition with BB5.1 (six mice each) for 5
weeks without additional immunosuppression. The treatment was
administered i.p. once a week, starting at day 1, with a dose of
20 mg/kg mAb in PBS. No loses or complications were observed in
the study. Grafts were collected 5 weeks post-transplantation,
formalin-ﬁxed and embedded in parafﬁn for histology. Sections
were H&E stained and evaluated independently by two in-
vestigators for signs of rejection.
Cell death determinations
Conﬂuent PAC were incubated in 12-well plates with 20% and
40% normal human serum (NHS) or the corresponding heat-
inactivated serum (hiHS) in HBSS at 37C. All cells were harvested
after 1, 8 and 24 h by 30-min treatment with collagenase II followed
by trypsin at 37C, washed and incubated with 2 mg/mL propidium
iodide (PI) in PBS for FACS analysis in a FACScalibur (BD Bio-
sciences). For apoptosis determination (sub-G1 analysis as
R. Sommaggio et al. / Osteoarthritis and Cartilage 21 (2013) 1958e19671960described6), conﬂuent PAC were incubated with 20% and 40% NHS
or hiHS in HBSS for 24 h at 37C.
Complement deposition
Conﬂuent PAC were trypsinized, washed and incubated with
20% and 40% NHS or hiHS in HBSS for 30 min at 37C. GAS914
(Novartis, Basel; Switzerland) was added into selected wells in
saturating concentration (100 mg/mL) to block anti-Gal antibodies.
For complement deposition determination, cells were stained with
FITC-conjugated anti-human C3 and anti-human C4 antibodies
(Cappel ICN, Costa Mesa, CA, USA), and anti-human SC5b-9 anti-
body (Quidel Corp., San Diego, CA, USA) followed by FITC-
conjugated goat anti-mouse IgG antiserum (Life technologies). To
assess human antibody deposition, we used FITC-conjugated anti-
human IgG and anti-human IgM antibodies (Life Technologies). MFI
was determined in a Gallios ﬂow cytometer with Kaluza software
(Beckman Coulter).Fig. 1. Effect of anti-C5 mAb on cartilage xenograft rejection. (A) Pharmacodynamic experime
0 and 7. Hemolytic complement activity was determined at indicated times in ﬁve BB5.1- or P
relative to baseline as mean with 95% CI. Statistically signiﬁcant differences were observed b
**P < 0.01). Particularly, the P values relative to the PBS cohort were from the ﬁrst time p
respectively. The effect of C5 inhibition was assessed by histologic analysis of control and
staining of the following sections is shown: control (B) and HT (D) cartilage harvested from
treated mice (n ¼ 6 each). Cartilage is labeled as TEC and the cellular inﬁltrate is indicatedExpression analyses
PAC characterization (including activation markers) was con-
ducted by FACs as described3,6. To activate PAC, conﬂuent PAC were
incubated in T25 ﬂasks with 20% and 40% NHS in HBSS, as well as
hiHS and 10 ng/ml human TNFa (R&D Systems) controls for 24 h, or
with human C5a (100 and 1000 ng/ml, R&D Systems) for 12 h. For
transduced PAC, a large populationwith high expression levels was
obtained from G418-selected cells by cell sorting in MoFlo-XDP
high-speed cell sorter (Beckman Coulter). Immunoﬂuorescence of
hCD59 was performed with anti-hCD59 mAb (BRA10G, Biodesign
International, Kennebunk, ME, USA) and goat anti-mouse IgG FITC-
conjugated antiserum as secondary antibody.
Cytokine determinations
Conﬂuent PAC, either control or genetically modiﬁed, were
incubated in 12-well plates at 37C with 20% and/or 40% NHS innt conducted to determine the effect of 20 mg/kg BB5.1 in Gal KO mice injected on days
BS-treated mice and three mice treated with isotype-matched (CN) mAb and expressed
etween BB5.1 treatment and corresponding controls with exception of day 7 (*P < 0.05,
oint (0.4 days) to the last (14 days) 0.0002, 0.0004, 0.00008, 0.0027, 0.192 and 0.038
HT tissue-engineered cartilage (TEC) s.c.-implanted in Gal KO mice for 5 weeks. H&E
untreated mice (n ¼ 7 each), control (C) and HT (E) cartilage harvested from BB5.1-
with arrows. The original magniﬁcation is 200.
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Systems) or exposed to hiHS were included as controls. After 8-
and/or 24-h incubations, culture supernatants were collected and
used for pig IL-6 (pIL-6) and IL-8 (pIL-8) determinations (in dupli-
cates) by ELISA with Quantikine immunoassays (R&D Systems).
These ELISA do not produce signiﬁcant cross-reactivity with human
IL-6 and IL-8. Similar procedures were conducted to study the effect
of human C5a, as well as that of anti-human C5 mAb 557 and 561
(Hycult Biotech) at 10 mg/ml and GAS914 at 100 mg/ml.
Statistical analysis
Values are presented as themean of single values corresponding
to each animal or independent experiment (analysis unit) and the
95% conﬁdence interval (95% CI) calculated for each data set. For the
ELISA results, the mean of duplicates of each condition was used.
Statistical analysis was conducted using two-tailed Satterthwaite’s t
test when comparing two groups, with exception of one speciﬁc
experiment for which a paired t-test was applied. ANOVA (applying
Tukey) was used for multiple comparisons. Differences were
considered statistically signiﬁcant at P  0.05.Fig. 2. PAC cell death mediated by NHS. (A) Mean with 95% CI of ﬁve independent
experiments analyzing PI incorporation in PAC treated with 20% and 40% NHS or hiHS
controls after harvest at indicated times. Statistical differences were calculated be-
tween NHS-treated PAC and corresponding hiHS controls and signiﬁcance is indicated
(*P  0.05). Particularly, the P values were respectively 0.039 and 0.05 for 1 and 24 h
with 20% serum, and 0.044, 0.37 and 0.28 for 1, 8 and 24 h at 40% serum. (B) Meanwith
95% CI of six independent experiments showing percentage of hypodiploid PAC
incubated with 20% and 40% NHS or hiHS for 24 h. Statistical differences were calcu-
lated between NHS-treated PAC and corresponding hiHS controls and signiﬁcance is
indicated (**P ¼ 0.01).Results
Anti-C5 therapy reduces the severity of rejection of xenogeneic
cartilage in Gal KO mice
To assess the effects of C5 inhibition in a pig-to-mouse model of
chondrocyte xenotransplantion3, we used the anti-mouse C5 mAb
BB5.1. BB5.1 efﬁcacy was assessed in a hemolytic assay incubating
Gal KO mouse serum containing natural anti-Gal antibodies with
rabbit erythrocytes, which express Gal antigen. In vitro, BB5.1
strongly inhibited the serum hemolytic activity at 20, 10 and 5 mg/Fig. 3. Human natural antibody and complement deposition on PAC. PAC incubated
with 20% NHS or hiHS with or without GAS914 (GAS) were analyzed by ﬂow cytometry
for deposition of human IgG and IgM (A), and complement components C4, C3 (B) and
C5b-9 (C). MFI of a representative experiment of 3 is shown (gated for alive cells). Bars
for IgG/IgM and C4/C3 are overlayed and the upper limit of each color depicts the
corresponding mean FL-1.
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(data not shown). In vivo, mice injected with either PBS or isotype-
matched mAb showed no major decline in complement activity
during the 2-week follow-up [Fig. 1(A)]. On the contrary, 20 mg/kg
BB5.1 once a week was sufﬁcient for complement inhibition in our
Gal KO mice.
To evaluate the effect of complement inhibition on the
rejection process of xenogeneic cartilage, control and HT engi-
neered pig cartilage was transplanted subcutaneously into Gal
KO mice and subgroups of mice were treated with BB5.1 for 5
weeks. Histological evaluation of the non-transgenic implants
retrieved 5 weeks post-transplantation from the untreated
cohort displayed extensive tissue destruction and a pronounced
mononuclear cellular inﬁltrate [Fig. 1(B)]. On the contrary,
treatment with BB5.1 ameliorated graft survival, as a reduced
amount of mononuclear immune cells in the control cartilage
implants was observed [Fig. 1(C)]. As described3, rejection of the
HT-transgenic grafts was limited to the periphery, where a
cellular inﬁltrate developed [Fig. 1(D)]. Although differences
between the HT-transgenic grafts from untreated and BB5.1-
treated cohorts were more difﬁcult to appreciate, the anti-C5
treatment seemed to provide some improvement by prevent-
ing tissue damage [Fig. 1(E)].
Human complement causes moderate PAC death
To study whether human complement kills porcine chon-
drocytes, control PAC were treated with 20% and 40% NHS or hiHS
internal controls for various times and analyzed for PI incorpora-
tion [Fig. 2(A)]. All experiments with NHS included the corre-
sponding hiHS devoid of complement activity by heat inactivation.
After 1-h incubation, only 40% NHS caused some cell death at this0 50 100 150 200 250 300
20%hiHS
20%NHS
Untreated
SLA I
0 10 20
pICA
0 10 200 50 100 150 200 250 300
C5a 1000
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Mean Fluore
0
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Fig. 4. Expression analyses of PAC exposed to human complement. Mean with 95% CI of
expression. (A) PAC untreated or exposed to 20% NHS and hiHS for 24 h (n ¼ 4 independent
PAC and signiﬁcance is indicated (P values shown in ﬁgure). Expression of pVCAM-1 was al
exposed to TNFa for 24 h or to human C5a at 100 and 1000 ng/ml for 12 h (n ¼ 4 indep
untreated PAC and signiﬁcance is indicated (P values shown in ﬁgure). Statistically signiﬁca
(P ¼ 0.04).time point (mean 11.2%). This percentage was much below that
observed when incubating porcine aortic endothelial cells with
the same NHS (50% death with 40% NHS after 1 h). On the con-
trary, we observed higher cell death at later time points, even with
20% NHS [Fig. 2(A)]. In particular, PAC death ranged from 7 to 14%
over background after 24-h incubation with 20% NHS and from 8
to 22% with 40% NHS. For further clariﬁcation of the mechanism of
cell death, we subsequently determined the amount of apoptosis
attained after incubating PAC for 24 h with NHS by measuring the
percentage of hypodiploid cells [Fig. 2(B)]. PAC consistently
showed a low level of apoptotic cell death that was negligible at
20% NHS.
Porcine chondrocytes activate human complement
We next determined deposition of human IgM, IgG and
various complement components on PAC incubated with 20%
NHS or hiHS (Fig. 3). Cell death was simultaneously assessed to
exclude related effects. Thus, PAC incubated with hiHS showed
mainly IgM and IgG reactivity. NHS pre-treatment with satu-
rating concentrations of GAS914 (to completely block anti-Gal
antibodies) markedly reduced immunoglobulin deposition on
alive PAC [Fig. 3(A)]. Substantial C4, C3 and C5b-9 reactivity was
also detected on alive cells after NHS exposure [Fig. 3(B, C)].
Furthermore, deposition of these complement components
increased at 40% serum and was up to three-fold higher in dead
(PI-positive) cells (data not shown). Lastly, GAS914 decreased
complement deposition in similar proportion to antibody on
NHS-treated PAC (60e70% for C4/C3, 40e50% for C5) [Fig. 3(B,
C)]. Remarkably, complement deposition remained well above
background on both alive and dead cells incubated with NHS
plus GAS914.30 40 50 60
AM-1
0 10 20 30 40
pVCAM-1
0.039
0.023
0.0004
0.019
0 10 20 30 4030 40 50 60
scence Intensity
0.028
.039
0.0006
0.001
0.0005
0.005
mean ﬂuorescence intensity associated to SLA-I, pICAM-1 and pVCAM-1 cell-surface
experiments). Statistical differences were calculated between the treated and untreated
so signiﬁcantly higher in NHS-treated than hiHS control (P ¼ 0.03). (B) PAC untreated,
endent experiments). Statistical differences were calculated between the treated and
nt differences were also attained for SLA-I and pVCAM-1 between the two C5a doses
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To assess whether complement activation had an effect on
expression of relevant activation markers, we incubated control
PAC with 20% and 40% NHS or hiHS for 24 h and measured swine
leukocyte antigen I (SLA-I), porcine ICAM-1 (pICAM-1) and
VCAM-1 (pVCAM-1) on the cell surface. Both adhesion mole-
cules were signiﬁcantly up-regulated by 20% [Fig. 4(A)] and 40%
NHS (data not shown) relative to untreated PAC, whereas SLA-I
followed a similar trend. However, increases were also
observed after exposure to hiHS. Thus, pVCAM-1 was the only
marker tested which attained statistically signiﬁcant differences
over the corresponding hiHS control. These results led us to
assess the direct effect of human C5a on expression of PAC
activation markers [Fig. 4(B)]. PAC responded to 12-h human C5a
treatment by increasing SLA-I, pICAM-1 and pVCAM-1 in a dose-
dependent manner, up to three-fold for SLA-I and pICAM-1 and
13-fold for pVCAM-1 at high C5a concentration. None of these
markers reached expression levels as high as after 24-h TNFa
treatment.
Porcine chondrocytes release inﬂammatory mediators after
complement activation
We measured the release of pIL-6 and pIL-8 after incubation of
PAC with 20% and 40% NHS for 8 and 24 h (Fig. 5). NHS at 20%
sufﬁced to trigger pIL-6/pIL-8 release by PAC, although 40% serumFig. 5. Release of pIL-6 and pIL-8 by NHS-treated PAC. Mean with 95% CI of pIL-6 (A)
and pIL-8 (B) in culture supernatants of PAC exposed to 20% and 40% NHS (n ¼ 4 in-
dependent experiments). Controls of untreated, TNFa- and hiHS-treated PAC were
included. Statistical differences were calculated between the NHS-treated PAC and the
corresponding hiHS controls and signiﬁcance is indicated (*P < 0.05, **P < 0.01).
Particularly, the P values for pIL-6 were respectively 0.048 and 0.006 for 8 and 24 h
with 20% serum, and 0.007 and 0.033 for 8 and 24 h at 40% serum. Regarding pIL-8, the
P values were respectively 0.046 and 0.008 for 8 and 24 h with 20% serum, and 0.0001
and 0.030 for 8 and 24 h at 40% serum.produced a stronger response. The effect was complement-
mediated as low cytokine secretion was detected after incubation
with hiHS. Interestingly, PAC responded early on with signiﬁcant
pIL-6/pIL-8 increases 8 h after serum exposure, whereas TNFa
needed a longer treatment time to attain the full stimulatory effect
(2e3-fold higher than with NHS).
To assess the contribution of Gal antigen to this response, we
determined PAC cytokine release after 24-h exposure to 40% NHS
with and without GAS914. GAS914 led to a signiﬁcant reduction
in pIL-6/pIL-8 secretion relative to NHS alone (about 55%).
Both C5a and C5b-9 trigger pIL-6/pIL-8 secretion by chondrocytes
The role of C5 was investigated in this setting. First, we
conﬁrmed that human C5a directly triggered pIL-6/pIL-8 release in
PAC [Fig. 6(A)]. The anti-human C5 mAb 561 speciﬁcally inhibited
this effect. We also found that anti-C5 mAb 557 and 561 were both
capable of partially inhibiting NHS-mediated pIL-6/pIL-8 release
by PAC, although 557 displayed a signiﬁcantly higher inhibitory
activity [Fig. 6(B)]. As the effect of these antibodies had not been
fully clariﬁed, we also assessed their capacity to inhibit C5b-9
generation by determining the protection conferred to porcine
aortic endothelial cells exposed to NHS. The 557 mAb showed a
partial inhibitory activity of complement-mediated lysis, whereas
561 had no effect at this level (data not shown). As these results
indicated the involvement of C5b-9, we next studied these effects
in genetically-engineered PAC expressing hCD59. High expression
of hCD59 was attained by cell sorting (mean ﬂuorescence intensity
of 95 relative to 7 of mock control), which resulted in lower
cytokine secretion when compared to mock-transduced PAC
[Fig. 6(C)]. The combination of C5b-9 blockade by hCD59 expres-
sion with that of C5a by anti-C5 mAb consistently led to the
highest reduction in pIL-6/pIL-8 release [Fig. 6(C)]. Counteracting
anti-Gal antibodies with GAS914 similarly protected hCD59-
expressing PAC.
These results lead us to propose a model of how C5 activation
affects cartilage which could also apply to OA and RA pathogenesis
(Fig. 7).
Discussion
In this work we found evidence for a relevant contribution of
complement activation in rejection of xenogeneic chondrocytes.
Targeting C5 reduced cellular rejection of pig cartilage implanted
subcutaneously into Gal KO mice. To elucidate the mechanisms,
cellular assays were conducted with PAC exposed to NHS that
showed that porcine chondrocytes are highly resistant to
complement-mediated lysis. Instead, PAC responded to comple-
ment activation by up-regulating activation markers and secreting
pro-inﬂammatory cytokines/chemokines that surely exacerbate
rejection. These ﬁndings are relevant for developing cell therapies,
particularly with chondrocytes. Xenogeneic chondrocytes/cartilage
could be exposed to host antibody and complement in multiple
clinical scenarios such as during the repair of facial and laryngeal
cartilage defects (modeled in our subcutaneous approach), and
when treating articular lesions (due to surgical intervention and/or
disease). Our demonstration that genetic engineering of the donor
cell controls complement effects indicates this is a surmountable
hurdle and encourages further development. Moreover, the simple
in vivo model and cellular assays utilized here provide valuable
information for better understanding the hurdles of articular
cartilage repair and inﬂammatory disease.
The anti-C5 therapy resulted in improved graft survival that was
accompanied by a reduced cellular immune inﬁltrate. The high
BB5.1 efﬁcacy could be explained by its potent anti-inﬂammatory
Fig. 6. Role of C5 on PAC pIL-6 and pIL-8 release. (A) Effect of human C5a on pIL-6 and pIL-8 release by PAC incubated for 8 h with or without anti-C5 mAb 561. Mean with 95% CI of
duplicates of a representative experiment of 3. (B) Mean with 95% CI of six independent experiments showing pIL-6 and pIL-8 released by PAC after incubation with 40% NHS or
hiHS for 24 h with or without anti-C5 mAb 557, 561 or isotype-matched control. Statistically signiﬁcant differences were observed using a paired t-test between NHS conditions
containing anti-C5 mAb 557 or 561 vs NHS, alone or with control mAb, as well as when comparing the effect of mAb 557 and 561 (P values shown in ﬁgure). (C) Representative
experiment of 3 showing pIL-6/pIL-8 secretion by PAC mock-transduced or expressing high levels of hCD59 after incubation with 40% NHS or hiHS for 24 h. Blocking reagents were
added when indicated.
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C5a production20. Notably, BB5.1 does not target C5a receptors. C5a
is a very potent chemotaxin for neutrophils and monocytes that
through C5aR (CD88) promotes their extravasation and activa-
tion15,27. Their release of multiple inﬂammatory mediators such as
TNFa and IL-1b results in cartilage extracellular matrix degradation
and chondrocyte activation6,17,28, further amplifying inﬂammation.
Furthermore, local complement activation augments antigen pre-
sentation and T cell responses15, which may affect survival of
xenogeneic cartilage. These mechanisms are all probably involved
to some degree in rejection of xenogeneic cartilage grafted in the
joint. In a similar way to our model in which the avascular cartilage
is surrounded by a vascularized bed of connective tissue, the
cellular response could reach the articular cartilage through the
synovial membrane, as well as from the bone marrow for full-
thickness defects. Nevertheless, the direct effect of complementactivation on xenogeneic chondrocytes was unknown despite it
may be especially relevant in the joint. Therefore, we also
addressed this question.
Our experiments demonstrated that PAC are particularly resis-
tant to complement-mediated lysis. This ﬁnding is consistent with
the slow rejection process described for pig cartilage in discordant
xenotransplantation models3,8. The effect cannot be explained by
the low levels of Gal antigen on PAC, as porcine corneal endothelial
cells show low Gal expression and are highly susceptible to NHS-
mediated lysis29. On the contrary, it appears as a particularity of
chondrocytes and is consistent with recent observations that
certain cartilage matrix components (NC4, PRELP) inhibit C9-
polymerization and MAC formation30,31. Our PAC were studied at
low passage and produce many extracellular matrix components,
possibly explaining the sublytic C5b-9 deposition after NHS expo-
sure. The low proportion of cell death observed was most probably
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Fig. 7. Scheme of the mechanisms triggered by C5 complement activation on chondrocytes. Complement activation can be produced by antibody (Ab) deposition or other means.
This process leads to formation of the MAC/C5b-9 resulting in cytolysis and cell death of a small proportion of chondrocytes and local C5a generation. Most chondrocytes respond to
C5a and C5b-9 by up-regulating activation markers (MHC class I, ICAM-1, VCAM-1) and secreting IL-6 and IL-8. C5a and IL-8 promote migration and activation of immune cells that
contribute to the inﬂammatory milieu by releasing multiple inﬂammatory mediators including TNFa that result in extracellular matrix degradation. The loss of extracellular matrix
is enhanced by the up-regulation of catabolic enzymes by IL-6 and C5b-9. C5a and TNFa contribute to local T cell activation.
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It would be interesting to clarify the C5b-9 signals affecting chon-
drocyte apoptosis and the role of extracellular matrix components
in future studies.
PAC responded to complement activation by up-regulating cell-
surface activation markers and secreting pIL-6 and pIL-8. Both C5a
and C5b-9 contributed to PAC inﬂammatory response and support
the concept that exposure to low amounts of antibody and com-
plement may sufﬁce to activate chondrocytes and exacerbate
rejection. This could have implications beyond xeno-
transplantation. In fact, we found no previous reports about C5a
direct activity on chondrocytes. In HUVEC, C5a increases expression
of various adhesion molecules, chemokines and cytokines32. In the
xenogeneic setting, porcine C5aR has been reported to respond
poorly to human C5a33, but. this is unclear from our results. As in
humans34, we conﬁrmed C5aR expression in PAC by RT-PCR (data
not shown). We did not assess expression of C5a-decoy-R C5L2, but
our ﬁndings show a predominantly pro-inﬂammatory effect of C5a
on chondrocytes suggesting a minor or no participation of C5L2.
Our data also demonstrated a major contribution of sublytic C5b-8/
C5b-9 in this setting. Thus, the pro-inﬂammatory response of
chondrocytes to C5a and C5b-9 reveal another mechanism by
which C5 enhances cellular rejection of xenogeneic cartilage. The
participation of donor C5 (generated by PAC) was not assessed, but
we cannot discard it may play a minor role. In this regard, we
conﬁrmed the inability of BB5.1 to inhibit pig complement activity
in a hemolytic assay (data not shown). Although C5a and C5b-9 are
the major effectors of complement-mediated injury15, it would be
interesting to assess the effect of C3 in future studies in this setting.
C3b deposition and/or local C3a generation may provide additional
signals that favor tissue damage15.
We propose a model of C5 acting at various levels to promote
inﬂammation and cartilage rejection. In general, our results agree
with the critical role described for C5 in OA and RA animalmodels19e21,24. However, this work encourages to broaden the
applicability of C5 inhibition to the chondrocyte transplant setting.
Furthermore, we believe our ﬁndings may also be helpful for better
understanding the molecular bases of inﬂammatory joint diseases.
In particular, a direct effect of complement components on chon-
drocytes may explain some of the protective effects previously
observed in mice deﬁcient for C5aR and C627. Our results with
CD59-expressing chondrocytes also agreewith a CD59 requirement
in the joint to prevent disease severity21. Thus, the processes that
trigger the initial complement activation may differ in xenogeneic
cartilage rejection and inﬂammatory joint diseases, but subsequent
effects may be shared. Interestingly, our ﬁnding that chondrocytes
release IL-6 in response to C5a and C5b-9 may help to understand
the enhanced degradation of cartilage extracellular matrix after
complement activation in OA28,35, which in turn could further
amplify complement activation through speciﬁc matrix compo-
nents21. This could add up to other inﬂammatory and catabolic
mechanisms reported to be enhanced by sublytic MAC in chon-
drocytes21, whereas the role of C5a on these additional processes
remains to be elucidated. Furthermore, the release of the potent
chemokine IL-8 and the up-regulation of adhesion molecules by
C5a would promote cellular immunity.
The Gal-antigen blockade was insufﬁcient to prevent the PAC
response, further emphasizing the need to control complement
activation. Although Gal KO PAC were not studied, the results with
GAS914 were clear. Our current ﬁndings are highly relevant for the
design of genetic modiﬁcations that avert rejection of xenogeneic
chondrocytes. We endorse the use of strategies that prevent local
complement activation based on transgenic expression of com-
plement regulatory molecules together with Gal-antigen blocking
strategies. This is a matter of debate, but we reach the same
conclusion as others working in solid organ xenotransplantation
that confront the problem of AHXR11,12. This work in a simpler
system may provide valuable information for development. In
R. Sommaggio et al. / Osteoarthritis and Cartilage 21 (2013) 1958e19671966particular, it demonstrates the efﬁcacy of anti-C5 therapy in a
xenogeneic model in the absence of hyperacute rejection and en-
courages its systemic use if local complement control cannot pre-
vent humoral rejection. The high safety and efﬁcacy of anti-C5
therapy in clinical allotransplantation further supports its use15,36.
Targeting C3 for long systemic complement inhibition poses major
hurdles by compromising defense mechanisms against pathogens,
but the additional control of local C3 byproducts may be of interest.
The development of similar approaches for articular disease may
also provide additional tools to promote survival of porcine chon-
drocytes used for cartilage repair.
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